Scientists develop male contraceptive pill – say it does not harm sex drive

A male contraceptive pill has been developed which is effective, safe and does not harm sex drive, scientists who developed it have announced using clinical findings.

The study, which was published in The Endocrine Society, was presented at ENDO 2018, the society’s annual meeting in Chicago.

According to a report by London-based newspaper Daily Telegraph, the new drug, called dimethandrolone undecanoate, or DMAU, includes a long-chain fatty acid which slows down the clearance, allowing just one dose to be taken each day.

In what has been described as a “major step forward”, the drug was successfully tested on 83 men for a month for the first time.

So far efforts to create a once-daily pill to mimic the mainstream female contraceptive have stalled because men metabolise and clear out the hormones it delivers too quickly.

It means temporary male contraception has relied on condoms alone, with the main hopes for future contraceptive developments resting on a long-acting injection or topical gel, both of which are also under development.

Like the pill for women, the experimental pill combines activity of an androgen – a male hormone such as testosterone – and a progestin.

Investigators at the University of Washington Medical Centre tested three doses of DMAU – 100, 200 and 400mg – on 100 healthy men between 18 to 50 years old, 83 of whom completed the study.
They were subject to blood sampling for hormone and cholesterol testing on the first and last days of the study.

At the highest dose of DMAU tested, 400 mg, subjects showed “marked suppression” of levels of their testosterone and two hormones required for sperm production.

The results showed that the pill worked only if taken with food.

Despite having low levels of circulating testosterone, very few subjects reported symptoms consistent with testosterone deficiency or excess,” said Professor Stephanie Page, senior investigator on the study.

These promising results are unprecedented in the development of a prototype male pill,” All groups taking DMAU experienced some weight gain, as well decreases in HDL (“good”) cholesterol.

However, all subjects passed their safety tests, including markers of liver and kidney function. “DMAU is a major step forward in the development of a once-daily ‘male pill’,” said Professor Page.

Longer term studies are currently underway to confirm that DMAU taken every day blocks sperm production,” she added.

Many men say they would prefer a daily pill as a reversible contraceptive, rather than long-acting injections or topical gels, which are also in development.”